LOXO-305, a next generation, highly selective, non-covalent BTK inhibitor in previously treated mantle cell lymphoma, waldenstrom's macroglobulinemia, and other non-hodgkin lymphomas: Results from the phase 1/2 BRUIN study Meeting Abstract
| Authors: | Wang, M.; Shah, N. N.; Alencar, A. J.; Gerson, J. N.; Patel, M. R.; Fakhri, B.; Jurczak, W.; Tan, X. N.; Lewis, K. L.; Fenske, T. S.; Coombs, C. C.; Flinn, I. W.; Lewis, D. J.; Le Gouill, S.; Palomba, M. L.; Woyach, J. A.; Pagel, J. M.; Lamanna, N.; Cohen, J. B.; Barve, M.; Ghia, P.; Eyre, T. A.; Yin, M.; Nair, B.; Tsai, D.; Ku, N. C.; Mato, A.; Cheah, C. Y. |
| Abstract Title: | LOXO-305, a next generation, highly selective, non-covalent BTK inhibitor in previously treated mantle cell lymphoma, waldenstrom's macroglobulinemia, and other non-hodgkin lymphomas: Results from the phase 1/2 BRUIN study |
| Meeting Title: | 62nd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 136 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2020 Dec 5-8 |
| Meeting Location: | Virtual |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2020-11-05 |
| Language: | English |
| ACCESSION: | WOS:000607205605029 |
| DOI: | 10.1182/blood-2020-134314 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 8 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work